Popular on TelAve
- FirstFruits Farms and Opal Partner with the Junior Basketball League to Empower Youth Through Nutrition and Sport
- Introducing AX USP 3.0: Axiros' Latest Advancement in TR-369/USP Technology
- Peachtree Immediate Care Opens Two New Locations in December
- Webinar Announcement: Navigating the New Investment Adviser AML Mandate: What Steps Should Investment Advisers Be Taking Now?
- Industry-Changing Multi-Benefit Service Platform for Technology Systems & AI Smart Devices Drives; 218% Revenue Growth for Tekumo: Stock Symbol: TKMO
- Somebody's Husband by Robbi Renee Earns Early Acclaim for Its Powerful Exploration of Love, Loss, and Healing
- OmegaBrand Introduces New Thermal Transfer Ribbons for Honeywell PC45t Printers
- Texas Center For Oral Surgery & Dental Implants Launches Redesigned Website to Enhance Patient Experience
- New Age of Law Firm Website Design
- Stan Fitzgerald: A Profile in Resilience and Leadership with VFAF Veterans for America First Organizational Support for a Presidential Pardon
Similar on TelAve
- NuNorm Announces Stop Soldier Suicide as This Year's EQUAL Grant Recipient
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
- "Cannabis Industry Dream Team" Launches GreenFlow Systems to Revolutionize Manufacturing Standards
- Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
- NaturismRE Introduces Global Accreditation Standards to Redefine Nudist and Naturist Venues
- The Dental Specialists in Newton, MA, Introduces Cutting-Edge 3Shape TRIOS 5 Intraoral Scanner
- Certified Nutraceuticals Partners with Colorado Researchers for Groundbreaking Study on KollaJell™ and Brain Health
- Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations,: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP)
- Watchdog Reviews Milestones in Exposing Psychiatric Human Rights Abuses in 2024
Neurolixis expands rare autism disorders research program
TelAve News/10830992
Neurolixis issued a new US patent for treatment of Fragile X syndrome with NLX-101
PARK RIDGE, N.J. - TelAve -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that the United States Patent and Trademark Office (USPTO) granted a patent (US11974992B2) covering the use of NLX-101, a clinical phase drug candidate, for treatment of Fragile X syndrome (FXS). FXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on TelAve News
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on TelAve News
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on TelAve News
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- Best Plant Varieties for Windbreaks and Shelterbelts
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- New-and-Improved Caribbean-Food Website Dishes Out Free Ground-Shipping Offer; Affiliate Program Garnished with Generous Commission
- 50th Mount Dora Arts Festival set for Feb 1 and 2, 2024
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on TelAve News
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
- Top Book Printer in Central Ohio announces expansion
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- "Cannabis Industry Dream Team" Launches GreenFlow Systems to Revolutionize Manufacturing Standards
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Source: Neurolixis, Inc.
0 Comments
Latest on TelAve News
- TimelyBill to Showcase Innovation at ITEXPO
- Moonshot Announces 6th Annual 2025 Rural Arizona Pitch Competition Tour with Bilingual Resources and Mentors
- The Dental Specialists in Newton, MA, Introduces Cutting-Edge 3Shape TRIOS 5 Intraoral Scanner
- Pikmykid Acquires Visitu to Enhance School Visitor Management Solutions
- Project EverGreen's SnowCare for Troops Program Helps Military Families Weather the Winter During Awareness Month in January
- Celebrate Love in Style: Introducing the Signature Summer Bundle for 2025 Weddings
- MileMark Explains Latest ABA Rules On Attorney Advertising
- The Annual Kingdom Day Parade Celebrates 40th Anniversary With Its " 40th Annual Kingdom Day Parade"
- Morningscore Secures $700k in Funding to Build the Next Generation of AI SEO and Expand Globally
- Certified Nutraceuticals Partners with Colorado Researchers for Groundbreaking Study on KollaJell™ and Brain Health
- GD Nationwide: 2024 Recap and 2025 Preview
- Preserving Mikaben's Legacy: A Plea For Unity And Respect
- Globally-renowned scholar Dalia Mogahed Joins Origins Consulting Group as Senior Adviser on Islamophobia
- Agreement for $27 Million in Funding for Expanding Clinic Acquisitions and Operations,: NRx Pharmaceuticals, Inc. Stock Symbol: NRXP)
- Author and Speaker El-Hajj Maurice Crawford Shabazz Releases New Book
- Newly formed Dave Aronberg Law taps Assistant U.S. Attorney Emily M. Walters as Partner
- USA Green Card Defends the Green Card Lottery as Vital to Opportunity and Diversity
- Watchdog Reviews Milestones in Exposing Psychiatric Human Rights Abuses in 2024
- The Nashville International Chopin Piano Competition Announces Its Second Edition
- Avoid the Quitter's Day Trap this January 10th by Adopting an Ingenious Method Used by Basketball Legend LeBron James: Wear an "I Promise" Wristband